-
Part 2 | Session 1 SELUTION DeNovo: 1-Year Results Comparing Sirolimus Balloon vs DES in PCI
-
Part 2 | Session 4 TRILUMINATE Pivotal Trial: Lessons Learned from Tricuspid TEER
-
Part 2 | Session 5 Real-World EVOQUE Outcomes from TVT Registry
-
Part 2 | Session 6 PASCAL Precision System in Complex Degenerative MR
-
Part 2 | Session 7 PREVUE-VALVE: Prevalence of Valvular Heart Disease in Older Americans
-
Part 2 | Session 9 Short-CUT: Lithotripsy Vs Cutting Balloon for CAD
-
Part 2 | Session 10 10-Year Mortality in NOBLE: PCI vs CABG for Left Main Disease
-
Part 2 | Session 11 1-Year ENCIRCLE TMVR Results with SAPIEN M3
-
Part 1 | Session 1 5 Trials That Will Change My Practice with Dr Mirvat Alasnag
-
Part 1 | Session 2 2 Trials That Will Change My Practice with Prof Rasha Al-Lamee
-
Part 1 | Session 3 3 Ways AI Will Change Your Practice
TCT 2025 — Dr Nadira Hamid (Minneapolis Heart Institute, US) and Dr Rahul P Sharma (Stanford University, US) review the late-breaking trial data shaping the future of structural heart disease.
The discussion highlights real-world results from TRISCEND and TRILUMINATE in tricuspid disease, 7-year PARTNER 3 durability outcomes in TAVR, national prevalence insights from the PREVUE-VALVE study, and new frontiers in mitral intervention with SUMMIT MAC. Together, they examine what the evidence means for safety, durability, patient selection, and clinical adoption.
Editor: Mirjam Boros
Videographer: Tom Green and Dan Brent
Support: This is an independent video produced by Radcliffe Cardiology.
Stay Updated with Our TCT 2025 Video Coverage
We’re bringing you independent, critical insights straight from TCT 2025.
Join Prof Nicolas Van Mieghem in Cardiology Conference Perspectives as he discusses what the late-breaking data could mean for your practice.
Don’t miss our short Expert Interviews with investigators, offering concise analyses and practical take-home messages.
Hear Dr Mirvat Alasnag and Dr Rasha Al-Lamee share their views on the data they believe will have the greatest impact on clinical practice.
Follow the hot topics driving innovation in interventional cardiology, and stay tuned for fresh perspectives, real-world insights and global viewpoints, all coming soon on Transcatheter Academy.
More from this programme
Part 1
Highlights
Part 2
Expert Interviews
Part 3
NVM Cardiology Conference Perspectives
A focused video series where Prof Nicolas Van Mieghem offers expert reflections on the most impactful late-breaking trials shaping interventional cardiology at TCT 2025.
Faculty Biographies
Nadira Hamid
Cardiologist & Director of the Echocardiography Core Laboratory
Dr Nadira Hamid is a non-invasive cardiologist specialising in advanced echocardiography and structural heart disease. She is Director of the Echocardiography Core Laboratory at the Minneapolis Heart Institute Foundation in Minneapolis, Minnesota, where she supports structural heart and valvular disease programmes through multimodality cardiac imaging.
Her clinical practice focuses on echocardiography-guided assessment and imaging support for transcatheter structural heart interventions, including aortic, mitral, and tricuspid valve procedures.
Current Roles and Responsibilities
Since January 2024, Dr Hamid has served as Director of the Echocardiography Core Laboratory at the Minneapolis Heart Institute Foundation. In this role, she oversees echocardiography imaging protocols, quality assurance, and clinical imaging support for structural heart disease and valvular heart disease programmes.
She works within a multidisciplinary heart team, integrating…
Rahul P Sharma Sharma
Interventional Cardiologist
Dr Rahul P Sharma is Professor of Medicine at Stanford University and an Interventional Cardiologist at Stanford Health Care, where he serves as Director of Structural Interventions and Associate Director of the Cardiac Catheterisation Laboratory.
With over a decade of experience in complex coronary and structural heart interventions, he has combined clinical leadership with academic medicine, progressing from Cedars-Sinai to Stanford, where he has held faculty positions since 2019.
Rahul is also Co-Founder of Synchron, a pioneering neurotechnology company developing minimally invasive brain–computer interfaces that restore communication and independence for people with paralysis. His work sits at the intersection of cardiovascular innovation, translational research, and transformative medical technologies.
Comments